dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· January 30, 2026

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

View original at finance.yahoo.com
“full year 2025 Dupixent global net sales increased 26% to $17.8 billion versus 2024”
Verbatim excerpt from the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Libtayo is the leading immunotherapy for non-melanoma skin cancers

    80% confidence

  • Libtayo is first and only immunotherapy approved for high-risk adjuvant cutaneous squamous cell carcinoma

    80% confidence

  • Regeneron has announced $7B+ in ongoing and planned domestic investments

    80% confidence

  • Dupixent has 1.4M+ active patients worldwide

    80% confidence

  • EYLEA sales decline driven by competitive pressures, compounded bevacizumab market share loss due to patient affordability constraints, patient transition to EYLEA HD, and lower net selling price

    80% confidence

  • Dupixent is the most widely used innovative branded antibody medicine worldwide

    80% confidence

  • Regeneron has approximately 45 product candidates in clinical development

    80% confidence

Data points we hold from this source

Sanofi · collaboration revenue5.9 billion_USD

Cité dans ces articles de Via News

Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,997
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,997 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results: Source | Via News | fr.via.news